Announced Mon, 27 Jul · 14:12 IST
Epigral Q1FY27 PAT jumps 25% YoY to Rs 99 Cr, Rs 600 Cr capex approved
Compliance View source PDF
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.6%1-day move
₹1163.00
prior close
₹1176.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.1+0.3-0.1+0.6—————————
Up moveDown movePending
AI summary
Epigral posted Q1FY27 revenue of Rs 709 Cr, up 15% YoY, with PAT rising 25% to Rs 99 Cr. EBITDA grew 10% to Rs 179 Cr at 25% margin. Sales volume grew 5% with plant utilization above 80%. Net Debt/EBITDA stood at 0.8x. Board approved Rs 600 Cr capex for a 1,25,000 TPA Epoxy Resin plant and a Multi-Purpose Plant, with commissioning targeted for H2FY28. Pilot plant expected by Q2FY27. Expansion leverages internal raw materials.
Likely market impact
Strong Q1 results with 25% PAT growth plus Rs 600 Cr forward-integration capex signal confidence in specialty chemicals expansion.